tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

3 Small-Cap Stocks That Could Double Your Money, According to Analysts

Story Highlights

Analysts see strong upside potential in these three small-cap stocks.

3 Small-Cap Stocks That Could Double Your Money, According to Analysts

Small-cap stocks often fly under the radar, but some are now drawing attention from Wall Street. Analysts have identified three such companies with strong fundamentals and growth potential, each offering more than 100% upside from current levels.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Let’s dive into the details. Click on any ticker to explore each stock further and decide if it deserves a spot in your portfolio.

HIVE Digital Technologies (HIVE)

Hive Digital Technologies is a blockchain and digital asset company focused on cryptocurrency mining, decentralized finance, and innovative digital solutions. Year-to-date, HIVE stock has declined by 23%.

Overall, six out of seven analysts currently covering HIVE stock have issued Buy recommendations. Meanwhile, the average HIVE stock price target of $6.38 suggests over 190% upside from current levels.

See more HIVE analyst ratings

Powerfleet (AIOT) 

Powerfleet delivers Internet of Things (IoT) software-as-a-service (SaaS) solutions across various industries. AIOT stock has declined by 32% so far in 2025.

Yesterday, three top-rated analysts confirmed their Buy ratings on AIOT stock. Overall, the stock has seven Buy and one Hold recommendations. Meanwhile, Powerfleet’s average stock price target of $9.58 suggests a potential upside of 113.84% from current levels.

See more AIOT analyst ratings

Beam Therapeutics (BEAM)

Beam Therapeutics is a biotechnology company focused on precision genetic medicines. Year-to-date, BEAM stock has declined by 30%.

Overall, 11 out of 14 analysts rate BEAM stock as a Buy. The average Beam Therapeutics’ stock price target of $40.92 implies a potential upside of 135.0% from current levels.

See more BEAM analyst ratings

Disclaimer & DisclosureReport an Issue

1